Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Crispr Therapeutics Ag's Business Segments
Crispr Therapeutics Ag's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
2
Largest Segment
Member
Total Revenue
$ 10
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Member0%
- Collaboration Revenue6.3%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Member | $ 11 | - |
| Collaboration Revenue | $ 1 | 6.3% |
Revenue by Product & Service Category - FY
- Collaboration Revenue68.6%
- Grant31.4%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Collaboration Revenue | $ 1 | 68.6% |
| Grant | $ 0 | 31.4% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Member0%
- Collaboration Revenue6.3%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Member | $ 11 | - |
| Collaboration Revenue | $ 1 | 6.3% |
Description of Crispr Therapeutics Ag
Crispr Therapeutics AG is a leading biotechnology company that focuses on developing transformative gene-based medicines using the revolutionary CRISPR/Cas9 gene editing technology. The company was founded in 2013 and is based in Switzerland.
CRISPR/Cas9 is a genome editing system that allows scientists to make precise changes to DNA sequences in living organisms. It enables modification of genes in a highly targeted manner, offering immense potential in treating a wide range of genetic disorders and diseases.
Crispr Therapeutics AG's mission is to translate the immense power of CRISPR/Cas9 into effective therapies for patients with serious medical conditions. The company is dedicated to developing breakthrough treatments that address the root causes of genetic diseases, providing long-lasting and potentially curative solutions.
The company has built a strong portfolio of therapeutic candidates across different disease areas, including hemoglobinopathies, immuno-oncology, regenerative medicine, and rare genetic diseases. One of their most notable candidates is CTX001, an investigational gene therapy for beta-thalassemia and sickle cell disease, where they have partnered with Vertex Pharmaceuticals.
Crispr Therapeutics AG employs a multidisciplinary approach, combining expertise in molecular biology, biochemistry, genetics, and clinical development to advance their therapeutic pipeline. Their research and development efforts involve using CRISPR/Cas9 to modify and enhance cells in the laboratory, which can be later administered to patients as personalized therapies.
The company's innovative and proprietary technology offers several advantages over traditional gene therapy approaches, as it provides precise and specific editing capabilities, higher efficiency, and potential for reversibility. These unique features increase the safety and efficacy of their therapeutic interventions.
Crispr Therapeutics AG is also actively engaged in collaborations and partnerships with leading academic institutions, pharmaceutical companies, and research organizations to further advance the field of gene editing and accelerate the development of new therapies. This collaborative approach enhances the knowledge-sharing and supports the progression of CRISPR-based technologies.
The company is committed to rigorous regulatory and ethical standards, ensuring the application of gene editing technology is carried out responsibly and in line with the highest scientific and medical standards. They prioritize patient safety and aim to deliver transformative treatments that have the potential to improve the lives of millions of people worldwide.
In summary, Crispr Therapeutics AG is a cutting-edge biotechnology company that harnesses the power of CRISPR/Cas9 gene editing technology to develop novel and potentially curative therapies for various genetic diseases and conditions. Their extensive research, strong partnerships, and commitment to patient well-being position them as a leading player in the field of gene-based medicine.
CRISPR/Cas9 is a genome editing system that allows scientists to make precise changes to DNA sequences in living organisms. It enables modification of genes in a highly targeted manner, offering immense potential in treating a wide range of genetic disorders and diseases.
Crispr Therapeutics AG's mission is to translate the immense power of CRISPR/Cas9 into effective therapies for patients with serious medical conditions. The company is dedicated to developing breakthrough treatments that address the root causes of genetic diseases, providing long-lasting and potentially curative solutions.
The company has built a strong portfolio of therapeutic candidates across different disease areas, including hemoglobinopathies, immuno-oncology, regenerative medicine, and rare genetic diseases. One of their most notable candidates is CTX001, an investigational gene therapy for beta-thalassemia and sickle cell disease, where they have partnered with Vertex Pharmaceuticals.
Crispr Therapeutics AG employs a multidisciplinary approach, combining expertise in molecular biology, biochemistry, genetics, and clinical development to advance their therapeutic pipeline. Their research and development efforts involve using CRISPR/Cas9 to modify and enhance cells in the laboratory, which can be later administered to patients as personalized therapies.
The company's innovative and proprietary technology offers several advantages over traditional gene therapy approaches, as it provides precise and specific editing capabilities, higher efficiency, and potential for reversibility. These unique features increase the safety and efficacy of their therapeutic interventions.
Crispr Therapeutics AG is also actively engaged in collaborations and partnerships with leading academic institutions, pharmaceutical companies, and research organizations to further advance the field of gene editing and accelerate the development of new therapies. This collaborative approach enhances the knowledge-sharing and supports the progression of CRISPR-based technologies.
The company is committed to rigorous regulatory and ethical standards, ensuring the application of gene editing technology is carried out responsibly and in line with the highest scientific and medical standards. They prioritize patient safety and aim to deliver transformative treatments that have the potential to improve the lives of millions of people worldwide.
In summary, Crispr Therapeutics AG is a cutting-edge biotechnology company that harnesses the power of CRISPR/Cas9 gene editing technology to develop novel and potentially curative therapies for various genetic diseases and conditions. Their extensive research, strong partnerships, and commitment to patient well-being position them as a leading player in the field of gene-based medicine.
Crispr Therapeutics AG is a prominent biotechnology company at the forefront of developing innovative gene-based medicines leveraging its proprietary CRISPR technology. The company is structured around several key segments, each offering diverse products and services tailored to tackle various medical challenges, particularly in genetic disorders. Below is an in-depth overview of these segments and their respective offerings.
1. Therapeutic Programs
Crispr Therapeutics is dedicated to advancing transformative gene therapies for a range of genetic disorders. Their therapeutic programs are focused on several key areas:
- Rare Blood Disorders: One of their primary focuses is on blood disorders, notably beta-thalassemia and sickle cell disease. They are developing investigational therapies designed to correct genetic mutations at the root of these conditions to restore normal hemoglobin function and improve patients quality of life.
- Immuno-Oncology: Crispr is also exploring ways to harness the power of the immune system to combat cancer. Through innovative gene editing approaches, they are developing therapies aimed at modifying immune cells to target and destroy cancer cells more effectively.
- Regenerative Medicine: This segment involves research aimed at regenerating or repairing damaged tissues and organs through gene editing techniques. The goal is to treat a variety of conditions where cellular repair or replacement is beneficial.
- Other Genetic Diseases: Crispr Therapeutics is investing in developing therapies for other genetic diseases, expanding their therapeutic reach to various hereditary and metabolic disorders.
Gene Editing Technology
Crispr Therapeutics is a leader in CRISPR/Cas9 gene editing technology. Their product offerings in this area include:
- CRISPR/Cas9 Systems: They provide state-of-the-art tools for researchers interested in gene editing, offering customizable CRISPR libraries and components for gene knockouts, knock-ins, and other genomic modifications.
- Consulting and Technical Services: The company offers technical support and consulting services to assist researchers in optimizing their gene editing experiments, which can include help with vector design, protocol establishment, and experimental design.
Intellectual Property
Crispr Therapeutics boasts a comprehensive intellectual property portfolio surrounding CRISPR technology, which is critical for its competitive edge. Their offerings include:
- Licensing Opportunities: The company provides licensing options for institutions and businesses wishing to utilize their innovative gene editing technologies. This enables external developers to leverage patented methodologies for their therapeutic research.
- Research Collaborations: Crispr Therapeutics engages in collaborative agreements with academic institutions and private companies for joint research and product development, effectively broadening the application of their technologies.
Preclinical and Clinical Studies
Crispr Therapeutics is heavily involved in robust preclinical and clinical research processes, offering the following services:
- Preclinical Research Programs: The company conducts extensive research to evaluate the safety and efficacy of their therapeutic candidates. This involves various in vitro (test tube or culture dish) and in vivo (living organism) studies.
- Clinical Trials: They actively manage clinical trials that rigorously test the effects of their therapies on patients. This includes all phases of clinical studies, from initial safety assessments to large-scale efficacy trials.
Partnerships and Collaborations
Crispr Therapeutics AG recognizes the importance of collaboration in biotechnology:
- Industry Collaborations: They establish partnerships with pharmaceutical companies to co-develop therapies, pooling resources and expertise to accelerate research timelines.
- Academic Collaborations: The company also partners with leading academic institutions, fostering innovation through shared research projects and expertise exchange.
Manufacturing and Supply Chain
To ensure the successful development and commercialization of their therapies, Crispr Therapeutics has developed:
- Manufacturing Facilities: They operate advanced facilities capable of producing clinical-grade materials critical for their gene therapy products. This is essential for both preclinical and clinical applications.
- Robust Supply Chain Management: The company has built an efficient supply chain to guarantee the availability of necessary components for gene therapy manufacturing, ensuring consistency and quality in their therapeutic offerings.
Conclusion
Overall, Crispr Therapeutics AG is committed to advancing the field of gene-based medicine through a comprehensive suite of products and services. Their therapeutic programs target a broad spectrum of genetic disorders, while their cutting-edge gene editing technology, intellectual property strategies, rigorous research methodologies, and collaborative efforts position the company as a leader in the biotechnology landscape. By integrating manufacturing capabilities and supply chain management, Crispr Therapeutics is well-equipped to bring innovative treatments to market, aiming to transform patient outcomes in the realm of genetically-driven diseases.
1. Therapeutic Programs
Crispr Therapeutics is dedicated to advancing transformative gene therapies for a range of genetic disorders. Their therapeutic programs are focused on several key areas:
- Rare Blood Disorders: One of their primary focuses is on blood disorders, notably beta-thalassemia and sickle cell disease. They are developing investigational therapies designed to correct genetic mutations at the root of these conditions to restore normal hemoglobin function and improve patients quality of life.
- Immuno-Oncology: Crispr is also exploring ways to harness the power of the immune system to combat cancer. Through innovative gene editing approaches, they are developing therapies aimed at modifying immune cells to target and destroy cancer cells more effectively.
- Regenerative Medicine: This segment involves research aimed at regenerating or repairing damaged tissues and organs through gene editing techniques. The goal is to treat a variety of conditions where cellular repair or replacement is beneficial.
- Other Genetic Diseases: Crispr Therapeutics is investing in developing therapies for other genetic diseases, expanding their therapeutic reach to various hereditary and metabolic disorders.
Gene Editing Technology
Crispr Therapeutics is a leader in CRISPR/Cas9 gene editing technology. Their product offerings in this area include:
- CRISPR/Cas9 Systems: They provide state-of-the-art tools for researchers interested in gene editing, offering customizable CRISPR libraries and components for gene knockouts, knock-ins, and other genomic modifications.
- Consulting and Technical Services: The company offers technical support and consulting services to assist researchers in optimizing their gene editing experiments, which can include help with vector design, protocol establishment, and experimental design.
Intellectual Property
Crispr Therapeutics boasts a comprehensive intellectual property portfolio surrounding CRISPR technology, which is critical for its competitive edge. Their offerings include:
- Licensing Opportunities: The company provides licensing options for institutions and businesses wishing to utilize their innovative gene editing technologies. This enables external developers to leverage patented methodologies for their therapeutic research.
- Research Collaborations: Crispr Therapeutics engages in collaborative agreements with academic institutions and private companies for joint research and product development, effectively broadening the application of their technologies.
Preclinical and Clinical Studies
Crispr Therapeutics is heavily involved in robust preclinical and clinical research processes, offering the following services:
- Preclinical Research Programs: The company conducts extensive research to evaluate the safety and efficacy of their therapeutic candidates. This involves various in vitro (test tube or culture dish) and in vivo (living organism) studies.
- Clinical Trials: They actively manage clinical trials that rigorously test the effects of their therapies on patients. This includes all phases of clinical studies, from initial safety assessments to large-scale efficacy trials.
Partnerships and Collaborations
Crispr Therapeutics AG recognizes the importance of collaboration in biotechnology:
- Industry Collaborations: They establish partnerships with pharmaceutical companies to co-develop therapies, pooling resources and expertise to accelerate research timelines.
- Academic Collaborations: The company also partners with leading academic institutions, fostering innovation through shared research projects and expertise exchange.
Manufacturing and Supply Chain
To ensure the successful development and commercialization of their therapies, Crispr Therapeutics has developed:
- Manufacturing Facilities: They operate advanced facilities capable of producing clinical-grade materials critical for their gene therapy products. This is essential for both preclinical and clinical applications.
- Robust Supply Chain Management: The company has built an efficient supply chain to guarantee the availability of necessary components for gene therapy manufacturing, ensuring consistency and quality in their therapeutic offerings.
Conclusion
Overall, Crispr Therapeutics AG is committed to advancing the field of gene-based medicine through a comprehensive suite of products and services. Their therapeutic programs target a broad spectrum of genetic disorders, while their cutting-edge gene editing technology, intellectual property strategies, rigorous research methodologies, and collaborative efforts position the company as a leader in the biotechnology landscape. By integrating manufacturing capabilities and supply chain management, Crispr Therapeutics is well-equipped to bring innovative treatments to market, aiming to transform patient outcomes in the realm of genetically-driven diseases.